Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021.
Sign Up to like & getrecommendations! Published in 2021 at "European urology"
DOI: 10.1016/j.eururo.2021.02.032
Abstract: Men with metastatic germ cell tumors undergoing chemotherapy are at high risk of venous thromboembolic events and low risk of bleeding. A central venous-access device should be avoided whenever possible. Thromboprophylaxis may be prescribed after… read more here.
Keywords: metastatic germ; central venous; germ cell; urology ... See more keywords
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Oncology"
DOI: 10.1093/annonc/mdy071
Abstract: Abstract Background Our prior Systemic Treatment Options for Cancer of the Prostate systematic reviews showed improved survival for men with metastatic hormone-naive prostate cancer when abiraterone acetate plus prednisolone/prednisone (AAP) or docetaxel (Doc), but not… read more here.
Keywords: systemic treatment; network; treatment; metastatic hormone ... See more keywords
Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Urology"
DOI: 10.1111/iju.14568
Abstract: To evaluate the efficacy and safety of enzalutamide plus androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer. read more here.
Keywords: men metastatic; deprivation therapy; metastatic hormone; androgen deprivation ... See more keywords
Development and validation of circulating tumor cell (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.6_suppl.157
Abstract: 157Background: We evaluated the prognostic significance of circulating tumor cell (CTC) number as determined on the Epic Sciences platform in men with metastatic castration resistant prostate cance... read more here.
Keywords: castration resistant; tumor cell; metastatic castration; circulating tumor ... See more keywords